收稿日期: 2024-03-11
录用日期: 2024-09-24
网络出版日期: 2024-10-28
基金资助
国家自然科学基金(82304021)
miR-128-3p inhibits the proliferation of keratinocytes in psoriasis via repressing leptin
Received date: 2024-03-11
Accepted date: 2024-09-24
Online published: 2024-10-28
Supported by
National Natural Science Foundation of China(82304021)
目的·探究miR-128-3p/瘦素(leptin,LEP)轴对银屑病中角质形成细胞过度增殖及炎症反应的调控作用。方法·选取BALB/c小鼠,分为对照组(n=10)及模型组(n=10)。模型组小鼠背部行咪喹莫特软膏连续涂抹以构建银屑病小鼠模型。构建miR-128-3p过表达和干扰质粒、LEP干扰质粒分别转染人永生化角质形成细胞HaCaT细胞。经实时定量聚合酶链反应检测miR-128-3p及LEP的mRNA,Western blotting检测LEP蛋白表达;酶联免疫吸附实验检测培养液中肿瘤坏死因子α(tumor necrosis factor α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)、IL-1β的含量;MTT实验检测细胞相对活力;EdU实验检测细胞增殖;采用双荧光素酶报告基因实验验证miR-128-3p与LEP的靶向关系。结果·与对照组小鼠比,模型组小鼠miR-128-3p表达下调,Lep的基因表达及蛋白水平升高(均P<0.05)。双荧光素酶报告基因实验证实LEP是miR-128-3p下游靶点。与模拟物阴性对照(negative control of mimic,NC mimic)组相比,miR-128-3p模拟物(miR-128-3p mimic)组miR-128-3p表达上调,LEP的基因表达及蛋白降低;miR-128-3p mimic组TNF-α、IL-6、IL-1β显著低于NC mimic;miR-128-3p上调后细胞相对活力、EdU阳性细胞率均降低(均P<0.05)。与抑制物阴性对照(negative control of inhibitor,NC inhibitor)组相比,miR-128-3p抑制物(miR-128-3p inhibitor)组miR-128-3p表达下调,LEP的基因表达及蛋白水平增加;miR-128-3p下调后细胞TNF-α、IL-6、IL-1β升高;miR-128-3p表达下调导致细胞相对活力和EdU阳性细胞率增加(均P<0.05)。进一步实验结果显示:与LEP抑制物(LEP inhibitor)组相比,miR-128-3pinhibitor+ LEP inhibitor组LEP表达上调,而TNF-α、IL-6、IL-1β水平升高,细胞相对活力及EdU阳性细胞率增加(均P<0.05)。结论·miR-128-3p靶向沉默LEP抑制角质形成细胞增殖及炎症反应,抑制银屑病发生发展。
关键词: 银屑病; 瘦素; 微小RNA-128-3p; 角质形成细胞
彭静 , 尹婧 , 夏萍 , 陈柳青 . miR-128-3p靶向沉默瘦素抑制银屑病角质形成细胞增殖及炎症反应[J]. 上海交通大学学报(医学版), 2024 , 44(10) : 1241 -1248 . DOI: 10.3969/j.issn.1674-8115.2024.10.005
Objective ·To explore the role of miR-128-3p/leptin (LEP) axis in the proliferation and inflammation of keratinocytes in psoriasis. Methods ·BALB/c mice were randomly divided into a control group (n=10) and a model group (n=10). Mice in the model group were given imiquimod on the back. miR-128-3p overexpression and interference plasmids, as well as LEP interference plasmids, were constructed and transfected into HaCaT cells, respectively. miR-128-3p and LEP mRNA were quantified by real-time quantitative polymerase chain reaction, and LEPprotein levels were detected by using Western blotting. Enzyme-linked immunosorbent assay was used to measure the content of tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in the culture medium. MTT assay was used to evaluate cell activity and EdU assay was to used to test cell proliferation. The binding site between miR-128-3p and LEP was determined by using a dual luciferase reporter gene assay. Results ·Compared with mice in the control group, mice in the model group showed downregulated expression of miR-128-3p and upregulated expression of LEP at both RNA and protein levels (all P<0.05). The dual luciferase reporter gene assay confirmed that LEP was a downstream target of miR-128-3p. Compared with the negative control mimic (NC mimic) group, expression of miR-128-3p was up-regulated in the miR-128-3p mimic group, and expression of LEP was reduced. The levles of TNF-α, IL-6, and IL-1β were significantly lower in the miR-128-3p mimic group than in the NC mimic group. The relative cell viability and EdU-positive cell rate were also reduced after miR-128-3p up-regulation (all P<0.05). Compared with the negative control inhibitor (NC inhibitor) group, expression of miR-128-3p was down-regulated in the miR-128-3p inhibitor group, and expression of LEP was increased. The levles of TNF-α, IL-1β and IL-6 were increased after miR-128-3pdownregulation. miR-128-3p down-regulation led to an increase in relative cell viability and EdU-positive cell rate (all P<0.05). Further experimental results showed that LEP expression was up-regulated in the miR-128-3p inhibitor+LEP inhibitor group compared with that in the LEP inhibitor group, whereas the levels of TNF-α, IL-6, and IL-1β were elevated, and the relative viability of the cells and the rate of EdU-positive cells were increased (all P<0.05). Conclusion ·miR-128-3p downregulates LEP to inhibit the proliferation and inflammatory response of keratinocytes, thereby inhibiting the occurrence and development of psoriasis.
Key words: psoriasis; leptin; miR-128-3p; keratinocyte
1 | GRIFFITHS C E M, ARMSTRONG A W, GUDJONSSON J E, et al. Psoriasis[J]. Lancet, 2021, 397(10281): 1301-1315. |
2 | TASHIRO T, SAWADA Y. Psoriasis and systemic inflammatory disorders[J]. Int J Mol Sci, 2022, 23(8): 4457. |
3 | THIRUMAL D, SINDHU R K, GOYAL S, et al. Pathology and treatment of psoriasis using nanoformulations[J]. Biomedicines, 2023, 11(6): 1589. |
4 | XIE W H, HUANG H, DENG X R, et al. Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational studies[J]. J Am Acad Dermatol, 2021, 84(3): 701-711. |
5 | NORDEN A, REKHTMAN S, STRUNK A, et al. Risk of psoriasis according to body mass index: a retrospective cohort analysis[J]. J Am Acad Dermatol, 2022, 86(5): 1020-1026. |
6 | PIETRZAK A, CHABROS P, GRYWALSKA E, et al. Serum lipid metabolism in psoriasis and psoriatic arthritis: an update[J]. Arch Med Sci, 2019, 15(2): 369-375. |
7 | CARUSO A, GELSOMINO L, PANZA S, et al. Leptin: a heavyweight player in obesity-related cancers[J]. Biomolecules, 2023, 13(7): 1084. |
8 | YAN H X, YU B, TIAN J L, et al. Serum leptin and adiponectin: indicators of cardiovascular disease secondary to psoriasis[J]. Indian J Dermatol, 2022, 67(2): 109-114. |
9 | CERMAN A A, BOZKURT S, SAV A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis[J]. Br J Dermatol, 2008, 159(4): 820-826. |
10 | YANG X L, WANG H L. miRNAs flowing up and down: the concerto of psoriasis[J]. Front Med, 2021, 8: 646796. |
11 | CHEN C, DENG Y, HU X G, et al. MiR-128-3p regulates 3T3-L1 adipogenesis and lipolysis by targeting Pparg and Sertad2[J]. J Physiol Biochem, 2018, 74(3): 381-393. |
12 | KIM S. LncRNA-miRNA-mRNA regulatory networks in skin aging and therapeutic potentials[J]. Front Physiol, 2023, 14: 1303151. |
13 | CHEN S S, WANG J L, ZHANG K L, et al. LncRNA Neat1 targets NonO and miR-128-3p to promote antigen-specific Th17 cell responses and autoimmune inflammation[J]. Cell Death Dis, 2023, 14(9): 610. |
14 | ORTIZ-LOPEZ L I, CHOUDHARY V, BOLLAG W B. Updated perspectives on keratinocytes and psoriasis: keratinocytes are more than innocent bystanders[J]. Psoriasis, 2022, 12: 73-87. |
15 | WANG F, GAO Y T, YUAN Y T, et al. MicroRNA-31 can positively regulate the proliferation, differentiation and migration of keratinocytes[J]. Biomed Hub, 2020, 5(2): 93-104. |
16 | MOSTAFA S A, MOHAMMAD M H S, NEGM W A, et al. Circulating microRNA203 and its target genes' role in psoriasis pathogenesis[J]. Front Med, 2022, 9: 988962. |
17 | JIN Z, HUANG Q S, PENG J, et al. MiR-125a-3p alleviates hyperproliferation of keratinocytes and psoriasis-like inflammation by targeting TLR4/NF-κB pathway[J]. Postepy Dermatol Alergol, 2023, 40(3): 447-461. |
18 | S?UCZANOWSKA-G?ABOWSKA S, STANISZEWSKA M, MARCHLEWICZ M, et al. Adiponectin, leptin and resistin in patients with psoriasis[J]. J Clin Med, 2023, 12(2): 663. |
19 | SU X, CHENG Y, CHANG D. The important role of leptin in modulating the risk of dermatological diseases[J]. Front Immunol, 2021, 11: 593564. |
20 | STJERNHOLM T, OMMEN P, LANGKILDE A, et al. Leptin deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes[J]. Exp Dermatol, 2017, 26(4): 338-345. |
21 | WATANABE Y, YAMAGUCHI Y, TAKAMURA N, et al. Leptin induces interleukin-6 production in keratinocytes via decreased expression of caveolin-1: a possible link between obesity and psoriatic inflammation[J]. Br J Dermatol, 2020, 183(4): 768-770. |
/
〈 |
|
〉 |